Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $6.8 million.

  • Arcturus Therapeutics Holdings' Current Deferred Revenue fell 7465.84% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 7465.84%. This contributed to the annual value of $19.5 million for FY2024, which is 5647.01% down from last year.
  • Arcturus Therapeutics Holdings' Current Deferred Revenue amounted to $6.8 million in Q3 2025, which was down 7465.84% from $11.3 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Current Deferred Revenue ranged from a high of $71.5 million in Q1 2024 and a low of $4.7 million during Q3 2022
  • Its 5-year average for Current Deferred Revenue is $32.3 million, with a median of $28.6 million in 2022.
  • In the last 5 years, Arcturus Therapeutics Holdings' Current Deferred Revenue surged by 91116.18% in 2021 and then tumbled by 9191.89% in 2022.
  • Arcturus Therapeutics Holdings' Current Deferred Revenue (Quarter) stood at $43.5 million in 2021, then plummeted by 34.12% to $28.6 million in 2022, then soared by 56.48% to $44.8 million in 2023, then tumbled by 56.47% to $19.5 million in 2024, then plummeted by 65.02% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q3 2025, $11.3 million for Q2 2025, and $12.7 million during Q1 2025.